Celltrion Pharmaceutical Reports Record Q3 Sales, Profit Growth
Seoul, South Korea – Celltrion pharmaceutical announced today record third-quarter results, posting sales of KRW 138.2 billion (approximately $106 million USD) adn operating profits of KRW 16.1 billion (approximately $12.3 million USD). This represents a 7.8% increase in sales and an 18.0% increase in operating profit compared to the same period last year, marking the highest quarterly performance in the company’s history.
The strong results were driven by successful new product launches,increased internal production capabilities,and expansion of its contract manufacturing organization (CMO) business,according to the company. Celltrion Pharmaceutical has been strategically focusing on both biosimilar and chemical drug growth and production to fuel growth.
The chemical business division contributed KRW 67.7 billion in sales, with hypertension treatment ‘Dilatren Tablet’ achieving KRW 15 billion in sales – a 16.5% year-over-year increase.
Biosimilar sales reached KRW 32.2 billion, a significant 48.2% increase year-over-year. ‘Remsima SC,’ the subcutaneous injection formulation of infliximab for autoimmune diseases, saw a 27.4% growth, contributing to a combined KRW 12.5 billion in sales for the entire Remsima product line (IV and SC).
Several newly launched biosimilars – including ‘Stechima’ (autoimmune disease), ‘Idengelt’ (eye disease), ‘Omriclo’ (allergic asthma), and ‘Stoboclo-Osenvelt‘ (bone disease) - collectively generated KRW 7.7 billion in sales during the quarter. Existing flagship products also demonstrated strong performance, with ‘Uplyma‘ (autoimmune disease) sales increasing 93.4% to KRW 1.9 billion and ‘Begzelma’ (anticancer drug) sales surging 236.3% to KRW 3.3 billion.
Consignment production revenue totaled KRW 38.2 billion, boosted by increased commercial production of pre-filled syringe (PFS) products like ‘Remsima SC’ (marketed as ‘Zimpentra’ in the US) and ‘Uplyma’ for global distribution.
“We recorded the highest quarterly performance ever due to stable growth of existing products and full-scale sales expansion of new products,” stated a Celltrion Pharmaceutical official. “We will continue to achieve lasting growth by strengthening our ability to produce high-quality products and increasing the competitiveness of our flagship products.”
The company also announced plans to increase investment in research and development (R&D) to further expand its product pipeline and maintain its growth trajectory.
